NCT04667533View on ClinicalTrials.gov

Desidustat in the Treatment of Chemotherapy Induced Anemia

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 11, 2020

Primary Completion Date

March 27, 2022

Study Completion Date

May 10, 2022

Conditions
Anemia of Chronic Kidney DiseaseChemotherapy Effect
Interventions
DRUG

Desidustat

"A total of 24 participants will be enrolled.~The study is divided into three cohorts as given below:~1. Cohort I: Single-dose 100 mg~2. Cohort II: Single-dose 150 mg~3. Cohort III: Single-dose 200 mg"

Trial Locations (1)

422002

HCG Manavata Cancer Centre,, Nashik

All Listed Sponsors
lead

Zydus Lifesciences Limited

INDUSTRY

NCT04667533 - Desidustat in the Treatment of Chemotherapy Induced Anemia | Biotech Hunter | Biotech Hunter